IIDEAYA Biosciences and Servier presented ESMO 2026 data from three darovasertib trials in metastatic uveal melanoma. The results broaden the drug’s potential patient population, but clinical development and commercialization remain dependent on subsequent trial and regulatory milestones.
At ESMO 2026, IDEAYA Biosciences and Servier presented data from three clinical trials evaluating darovasertib in uveal melanoma. The OptimUM-01 and OptimUM-02 results supported the potential of darovasertib plus crizotinib to provide clinical benefit in metastatic disease across HLA-A*02:01 allele status and lines of therapy.
The presentation adds to the companies’ effort to position darovasertib across the treatment journey of uveal melanoma, rather than limiting development to a single patient subgroup or treatment setting. The reported evidence includes OptimUM-01 data described as encouraging, alongside findings from OptimUM-02.
IDEAYA is developing darovasertib with Servier, while crizotinib is the combination partner in the reported regimen. The commercial significance for IDEAYA depends on whether the clinical findings translate into a registrational path and eventual treatment use in metastatic uveal melanoma.
The current evidence is clinical-trial data rather than an approval decision. The size and durability of benefit, the regulatory requirements, and the competitive treatment landscape remain important uncertainties as development continues.
Further trial updates, regulatory interactions and later-stage clinical milestones will determine whether the ESMO findings support a broader development strategy for darovasertib.
Our take
1 / 6
Our read · Oct 19
IDYA presented three darovasertib trial datasets supporting use with crizotinib across metastatic uveal melanoma patients.
Why
The read-through is strategic breadth rather than a near-term financial inflection: positive trial findings could expand darovasertib’s addressable metastatic uveal melanoma population, but the next value-bearing step is further clinical and regulatory validation. IDEAYA reported $218.7M of FY2025 revenue and a -52.0% net margin, so the company’s current financial profile does not by itself resolve the development outcome.
What could change this view
The clinical signal may fail to translate into a registrational or commercially viable treatment path, delaying any revenue contribution from darovasertib.
▲ The case it holds
The OptimUM-01 and OptimUM-02 findings support darovasertib plus crizotinib across HLA-A*02:01 allele status and lines of therapy, broadening the potential treatment population.
▼ The case it breaks
The evidence remains an interim clinical-development read, and IDEAYA’s FY2025 net margin was -52.0%, leaving execution and funding dependent on later milestones.
Reported by PR Newswire as IDEAYA Biosciences and Servier Announce Data From Three Clinical Trials at ESMO 2026 Supporting the Potential of Darovasertib to Become a Foundational New Therapy for Patients Across the Treatment Journey of Uveal Melanoma, . Who answers for this
Prices: 1D EOD · OCT 16 CLOSE, licensed end-of-day data.
Source: PR Newswire · Published here MON, OCT 19 · 6:00 AM ET · the only report in this record · How this is decided →
Photo: PR Newswire / file
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · reaction = the first close after a story against the close before it · nothing here is advice · How the Wire is made →
Photo credit ↓